Collet-Vidiella, R, Aguilar, LM, Lleix , C, Caballero-Avila, M, Illa, CT, Go i, EP, Llarch, P, Lluci -Carol, L, Tous, MS, Casasnovas, C, Guti rrez-Guti rrez, G, Fern ndez, JP, Carbayo, A, Gallardo, E, Vesperinas, A, Llanso, L, Fern ndez-Cadenas, I, Querol, L. Proteomic profiling of Guillain-Barre Syndrome using aptamers: Identifying and Validating Potential Biomarkers. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

De Lorenzo, A, Moretti, G, Bertini, A, Collet-Vidiella, R, Fasolino, A, Fortanier, E, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mira, V, Peric, S, Rajabally, Y, Sevilla, T, Tomaselli, P, Tozza, S, Pisciotta, C, Pareyson, D, Nobile-Orazio, E, Doneddu, P. Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Hernandez, EM, Maqueda, JC, Fonseca, E, Marco, C, Chico, J, Fernandez, JG, Llaurado, A, Cabello, J, del Pino, L, Izquierdo, C, Cortes, E, G llego, J, Ros, M, Cald , R, Pelayo, A, Vizcaino, CS, Hernandez, H, Alvarez, J, Simo, M, Dalmau, J, Bruna, J, Velasco, R. Immune checkpoint inhibitor-related myositis-myasthenia: A retrospective cohort study in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, AC. Efficacy of Riliprubart in chronic inflammatory demyelinating polyneuropathy: Phase 2 subgroup analyses. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Managing multifocal motor neuropathy: A survey of neurologists from Japan, Canada, and six European countries. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Reyes, V, Maurino, J, Armangu , T, Querol, L, Guti rrez-Guti rrez, G, Sotoca, J, Ares, A, Villaverde, R, Salas, E, D az-Abos, P, Cort s-Vicente, E, Gomez-Ballesteros, R, Ballesteros, J. Psychometric evaluation of resistance to change questionnaire: reluctance to adopt new treatments in myasthenia gravis. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Sacconi, S, Antozzi, C, Cortes-Vicente, E, Pascuzzi, R, Utsugisawa, K, Vissing, J, Vu, T, Bloemers, J, Grimson, F, Tarancon, T, Bril, V. Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Skripuletz, T, Allen, J, Rinaldi, S, Lauria, G, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Stettner, M, Lewis, R, van Doorn, P. Efgartigimod in pretreated patients with CIDP and progressive/relapsing or persistent disease activity. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).